Federal Register / Vol. 86, No. 145 / Monday, August 2, 2021 / Notices 41491 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Cordant Health Solutions, 2617 East L 

Street, Tacoma, WA 98421, 800–442– 

0438 (Formerly: STERLING Reference 

Laboratories) 

Desert Tox, LLC, 5425 E Bell Rd, Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare*, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630 (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387, 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Legacy Laboratory Services Toxicology, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088, Testing for Veterans Affairs 

(VA) Employees Only 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Redwood Toxicology Laboratory, 3700 

Westwind Blvd., Santa Rosa, CA 

95403, 800–255–2159 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on January 23, 2017 (82 FR 

7920). After receiving DOT certification, 

the laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Anastasia Marie Donovan, 

Policy Analyst, Division of Workplace 

Programs. 

[FR Doc. 2021–16385 Filed 7–30–21; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer at (240) 276– 

0361. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: Government 

Performance and Results Act (GPRA) 

Client/Participant Outcomes Measure— 

(OMB No. 0930–0208)—Revision 

SAMHSA is requesting approval to 

modify its existing CSAT Client-level 

GPRA instrument by removing 40 

questions and adding 41 questions to its 

existing CSAT Client-level GPRA 

instrument resulting in a net addition of 

1 question. Currently, the information 

collected from this instrument is 


khammond on DSKJM1Z7X2PROD with NOTICES
41492 Federal Register / Vol. 86, No. 145 / Monday, August 2, 2021 / Notices 

entered and stored in SAMSHA’s 

Performance Accountability and 

Reporting System, which is a real-time, 

performance management system that 

captures information on the substance 

abuse treatment and mental health 

services delivered in the United States. 

Continued approval of this information 

collection will allow SAMHSA to 

continue to meet Government 

Performance and Results Modernization 

Act of 2010 reporting requirements that 

quantify the effects and 

accomplishments of its discretionary 

grant programs, which are consistent 

with OMB guidance. 

SAMHSA will use the data for annual 

reporting required by GPRA and 

comparing baseline with discharge and 

follow-up data. GPRA requires that 

SAMHSA’s fiscal year report include 

actual results of performance 

monitoring for the three preceding fiscal 

years. The additional information 

collected through this process will 

allow SAMHSA to: (1) Report results of 

these performance outcomes; (2) 

maintain consistency with SAMHSAspecific performance domains, and (3) 

assess the accountability and 

performance of its discretionary grant 

programs including a focus on health 

equity. 

In revising the CSAT–GPRA tool, 

CSAT sought to improve functionality 

while also eliciting programmatic 

information that demonstrates impact at 

the client level. In this way, data from 

the revised GPRA tool can be used to 

assess resource allocation and to 

delineate who we serve, how we serve 

them, and how the program impacts 

clients from entry to discharge. The tool 

reflects CSAT’s desire to elicit pertinent 

client and program level data that can 

be used to not only guide future 

programs and practice, but to also 

respond to stakeholder, congressional 

and agency enquiries. 

TABLE 1—ESTIMATES OF ANNUALIZED HOUR BURDEN

SAMHSA tool Number of 

respondents 

Responses 

per 

respondent 

Total 

number of 

responses 

Burden 

hours per 

response 

Total 

burden 

hours 

Hourly wage 1

Total 

hour 

cost 

Baseline Interview Includes SBIRT Brief 

TX, Referral to TX, 

and Program-specific 

questions .................. 179,668 1 179,668 0.6 107,801 $24.78 $2,671,309 

Follow-Up Interview 

with Program-specific 

questions 2 ................ 143,734 1 143,734 0.6 86,240 24.78 2,137,027 

Discharge Interview 

with Program-specific 

questions 3 ................ 93,427 1 93,427 0.6 56,056 24.78 1,389,068 

SBIRT Program— 

Screening Only ......... 594,192 1 594,192 0.13 77,245 24.78 1,914,131 

SBIRT Program—Brief 

Intervention Only 

Baseline .................... 111,411 1 111,411 0.2 22,282 24.78 552,148 

SBIRT Program—Brief 

Intervention Only Follow-Up 2 .................... 89,129 1 89,129 0.2 17,826 24.78 441,728 

SBIRT Program—Brief 

Intervention Only Discharge 3 .................... 57,934 1 57,934 0.2 11,587 24.78 287,126 

CSAT Total ........... 1,269,495 ........................ 1,269,495 ........................ 379,037 ........................ 9,392,537 

1The hourly wage estimate is $21.23 based on the Occupational Employment and Wages, Mean Hourly Wage Rate for 21–1011 Substance 

Abuse and Behavioral Disorder Counselors = $24.78/hr. as of May 11, 2021. (http://www.bls.gov/oes/current/oes211011.htm. Accessed on May 

11, 2021.) 2 It is estimated that 80% of baseline clients will complete this interview. 

3 It is estimated that 52% of baseline clients will complete this interview. 

Note: Numbers may not add to the totals due to rounding and some individual participants completing more than one form. 

Send comments to Carlos D. Graham, 

SAMHSA Reports Clearance Officer, 

5600 Fishers Lane, Room 15E57–A, 

Rockville, Maryland 20857, OR email a 

copy to Carlos.Graham@

samhsa.hhs.gov. Written comments 

should be received by October 1, 2021. 

Carlos Graham, 

Social Science Analyst. 

[FR Doc. 2021–16405 Filed 7–30–21; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Project: Revision of Mental Health 

Client/Participant Outcome Measures 

and Infrastructure, Prevention, and 

Mental Health Promotion Indicators 

(OMB No. 0930–0285) 

SAMHSA is requesting approval for 

revisions to the previously approved 

instruments and data collection 

activities for the Government 

Performance and Results Act (GPRA) 

Center Mental Health Services (CMHS) 

(OMB No. 0930–0285) that expires on 

February 28, 2022. 


khammond on DSKJM1Z7X2PROD with NOTICES